TrimRx's Blog

Wegovy reduces liver fat by 59% in NAFLD patients via GLP-1 receptor modulation. Learn mechanisms, dose protocols, and realistic outcomes.

Wegovy reduces major cardiovascular events by 20% in high-risk patients — here’s the mechanism, trial data, and what cardiologists actually recommend.

Wegovy reduces blood pressure by 3–7 mmHg systolic through weight loss and improved vascular function — here’s what patients need to know about the effect.

Wegovy reduces liver fat by 24–38% in NAFLD patients through direct hepatic GLP-1 receptor activation — not just weight loss. Here’s the mechanism

Wegovy (semaglutide) reduces systemic inflammation markers like CRP and IL-6 by 20–30% through weight loss and direct anti-inflammatory pathways.

Wegovy’s cancer risk stems from animal thyroid tumors observed in rodent studies — not human clinical trials. Here’s what patients need to know.

Wegovy 5mg is a mid-titration dose in the semaglutide weight loss protocol, typically reached at week 8. Understand dosing, side effects, and what to

Wegovy carries a black box warning for medullary thyroid carcinoma risk based on rodent studies. We explain what this means for patients and who shouldn’t

Wegovy carries an FDA black box warning for thyroid C-cell tumors based on rodent studies. Human evidence remains limited but evolving—here’s the clinical